{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T05:13:22Z","timestamp":1789881202745,"version":"4.0.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-024-01492-1","type":"journal-article","created":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T06:58:54Z","timestamp":1730185134000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The efficacy and safety of anlotinib combined with chemotherapy in treatment of advanced soft tissue sarcoma"],"prefix":"10.1007","volume":"15","author":[{"given":"Ying","family":"Ni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yabing","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aijun","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhantong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,29]]},"reference":[{"key":"1492_CR1","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1002\/cncr.28657","volume":"120","author":"LA Doyle","year":"2014","unstructured":"Doyle LA. Sarcoma classification: an update based on the 2013 world health organization classification of tumors of soft tissue and bone. Cancer. 2014;120:1763\u201374.","journal-title":"Cancer"},{"key":"1492_CR2","doi-asserted-by":"publisher","first-page":"c7170","DOI":"10.1136\/bmj.c7170","volume":"341","author":"S Sinha","year":"2010","unstructured":"Sinha S, Peach AH. Diagnosis and management of soft tissue sarcoma. BMJ. 2010;341:c7170.","journal-title":"BMJ"},{"key":"1492_CR3","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1056\/NEJMra041866","volume":"353","author":"MA Clark","year":"2005","unstructured":"Clark MA, Fisher C, Judson I, Thomas JM. Soft-tissue sarcomas in adults. N Engl J Med. 2005;353:701\u201311.","journal-title":"N Engl J Med"},{"key":"1492_CR4","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/978-3-540-77960-5_14","volume":"179","author":"E Stoeckle","year":"2009","unstructured":"Stoeckle E, Coindre JM, Kind M, Kantor G, Bui BN. Evaluating surgery quality in soft tissue sarcoma. Recent Results Cancer Res. 2009;179:229\u201342.","journal-title":"Recent Results Cancer Res"},{"key":"1492_CR5","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/S1470-2045(17)30381-9","volume":"18","author":"WD Tap","year":"2017","unstructured":"Tap WD, Papai Z, Van Tine BA, Attia S, Ganjoo KN, Jones RL, et al. Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406\/SARC021): an international, multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2017;18:1089\u2013103.","journal-title":"Lancet Oncol"},{"key":"1492_CR6","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nature10144","volume":"473","author":"P Carmeliet","year":"2011","unstructured":"Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473:298\u2013307.","journal-title":"Nature"},{"key":"1492_CR7","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","volume":"379","author":"WT Van der Graaf","year":"2012","unstructured":"Van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379:1879\u201386.","journal-title":"Lancet"},{"key":"1492_CR8","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1016\/S1470-2045(16)30507-1","volume":"17","author":"O Mir","year":"2016","unstructured":"Mir O, Brodowicz T, Italiano A, Wallet J, Blay JY, Bertucci F, et al. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2016;17:1732\u201342.","journal-title":"Lancet Oncol"},{"key":"1492_CR9","doi-asserted-by":"publisher","first-page":"5233","DOI":"10.1158\/1078-0432.CCR-17-3766","volume":"24","author":"Y Chi","year":"2018","unstructured":"Chi Y, Fang Z, Hong X, Yao Y, Sun P, Wang G, et al. Safety and efficacy of anlotinib, a multikinase angiogenesis inhibitor, in patients with refractory metastatic soft tissue sarcoma. Clin Cancer Res. 2018;24:5233\u20138.","journal-title":"Clin Cancer Res"},{"key":"1492_CR10","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13045-018-0664-7","volume":"11","author":"G Shen","year":"2018","unstructured":"Shen G, Zheng F, Ren D, Du F, Dong Q, Wang Z, et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 2018;11:120.","journal-title":"J Hematol Oncol"},{"key":"1492_CR11","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1111\/cas.13536","volume":"109","author":"C Xie","year":"2018","unstructured":"Xie C, Wan X, Quan H, Zheng M, Fu L, Li Y, et al. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. Cancer Sci. 2018;109:1207\u201319.","journal-title":"Cancer Sci"},{"key":"1492_CR12","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S1470-2045(14)70063-4","volume":"15","author":"I Judson","year":"2014","unstructured":"Judson I, Verweij J, Gelderblom H, Hartmann JT, Sch\u00f6ffski P, Blay JY, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014;15:415\u201323.","journal-title":"Lancet Oncol"},{"key":"1492_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13569-016-0049-z","volume":"6","author":"KT Vo","year":"2016","unstructured":"Vo KT, Matthay KK, DuBois SG. Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcoma. Clin Sarcoma Res. 2016;6:9.","journal-title":"Clin Sarcoma Res"},{"key":"1492_CR14","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1093\/annonc\/mdr299","volume":"23","author":"CF Verschraegen","year":"2012","unstructured":"Verschraegen CF, Arias-Pulido H, Lee SJ, Movva S, Cerilli LA, Eberhardt S, et al. Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in datients with advanced or recurrent soft tissue sarcoma: the Axtell regimen. Ann Oncol. 2012;23:785\u201390.","journal-title":"Ann Oncol"},{"key":"1492_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26265","author":"C Kuo","year":"2017","unstructured":"Kuo C, Kent PM, Logan AD, Tamulonis KB, Dalton KL, Batus M, et al. Docetaxel, bevacizumab, and gemcitabine for very high risk sarcomas in adolescents and young adults: a single-center experience. Pediatr Blood Cancer. 2017. https:\/\/doi.org\/10.1002\/pbc.26265.","journal-title":"Pediatr Blood Cancer"},{"key":"1492_CR16","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1007\/s10637-018-0583-z","volume":"36","author":"X Garc\u00eda Del Muro","year":"2018","unstructured":"Garc\u00eda Del Muro X, Maurel J, Mart\u00ednez Trufero J, Lavernia J, L\u00f3pez Pousa A, de Las PR, et al. Phase II trial of ifosfamide in combination with the VEGFR inhibitor sorafenib in advanced soft tissue sarcoma: a Spanish group for research on sarcomas (GEIS) study. Invest New Drugs. 2018;36:468\u201375.","journal-title":"Invest New Drugs"},{"key":"1492_CR17","doi-asserted-by":"publisher","first-page":"102240","DOI":"10.1016\/j.eclinm.2023.102240","volume":"64","author":"X Bushu","year":"2023","unstructured":"Bushu X, Pan Q, Pan H, Li H, Li X, Chen J, Pang D, et al. Anlotinib as a maintenance treatment for advanced soft tissue sarcoma after first-line chemotherapy (ALTER-S006): a multicentre, open-label, single-arm, phase 2 trial. eClinicalMedicine. 2023;64:102240.","journal-title":"eClinicalMedicine"},{"key":"1492_CR18","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/S0959-8049(01)00083-1","volume":"37","author":"E Gortzak","year":"2001","unstructured":"Gortzak E, Azzarelli A, Buesa J, Bramwell VH, van Coevorden F, van Geel AN, et al. A randomised phase II study on neoadjuvant chemotherapy for \u2018High-Risk\u2019 adult soft-tissue sarcoma. Eur J Cancer. 2001;37:1096\u2013103.","journal-title":"Eur J Cancer"},{"key":"1492_CR19","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1093\/annonc\/mdh431","volume":"15","author":"SR Grobmyer","year":"2004","unstructured":"Grobmyer SR, Maki RG, Demetri GD, Mazumdar M, Riedel E, Brennan MF, et al. Neoadjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma. Ann Oncol. 2004;15:1667\u201372.","journal-title":"Ann Oncol"},{"key":"1492_CR20","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/S0360-3016(03)00186-X","volume":"56","author":"TF DeLaney","year":"2003","unstructured":"DeLaney TF, Spiro IJ, Suit HD, Gebhardt MC, Hornicek FJ, Mankin HJ, et al. Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas. Int J Radiat Oncol Biol Phys. 2003;56:1117\u201327.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1492_CR21","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1002\/cncr.26696","volume":"118","author":"JT Mullen","year":"2012","unstructured":"Mullen JT, Kobayashi W, Wang JJ, Harmon DC, Choy E, Hornicek FJ, et al. Long-term follow-up of patients treated with neoadjuvant chemotherapy and radiotherapy for large, extremity soft tissue sarcomas. Cancer. 2012;118:3758\u201365.","journal-title":"Cancer"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-024-01492-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-024-01492-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-024-01492-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T16:25:52Z","timestamp":1730219152000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-024-01492-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,29]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1492"],"URL":"https:\/\/doi.org\/10.1007\/s12672-024-01492-1","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,29]]},"assertion":[{"value":"9 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"598"}}